June 23 (Reuters) - Revolution Medicines Inc RVMD.O:
REVOLUTION MEDICINES ANNOUNCES FDA BREAKTHROUGH THERAPY DESIGNATION FOR DARAXONRASIB IN PREVIOUSLY TREATED METASTATIC PANCREATIC CANCER WITH KRAS G12 MUTATIONS
REVOLUTION MEDICINES INC - DESIGNATION BASED ON DATA FROM PHASE 1 TRIAL
REVOLUTION MEDICINES INC - PHASE 3 STUDY OF DARAXONRASIB EXPECTED TO COMPLETE ENROLLMENT THIS YEAR
Source text: ID:nGNX3z4Zt9
Further company coverage: RVMD.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.